{"product_id":"heart-shield-elite","title":"Heart Shield Elite","description":"\u003cdiv id=\"ai-summary\" style=\"background:#f0f7ff;border-left:4px solid #0057a8;padding:18px 22px;margin-bottom:28px;font-size:15px;line-height:1.7;color:#1a1a2e;\"\u003e\n\u003cstrong\u003eHeart Shield Elite — Advanced 360° Cardiovascular Risk Assessment (SGD 899)\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e\nHeart Shield Elite is EMIS+'s most comprehensive cardiovascular risk stratification protocol, integrating seven distinct biomarker domains, genetic polygenic risk scoring, non-invasive vascular imaging, and electrocardiographic assessment into a single coordinated clinical evaluation. The protocol quantifies both short-term (10-year Pooled Cohort Equations \/ SCORE2) and lifetime atherosclerotic cardiovascular disease (ASCVD) risk, then translates findings into a personalised cardiac protection protocol aligned with ACC\/AHA 2023, ESC\/EAS 2021, and Singapore MOH Cardiovascular Prevention Clinical Practice Guidelines.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eInflammatory and Cardiac Biomarker Panel:\u003c\/strong\u003e High-sensitivity C-reactive protein (hsCRP, IFCC-standardised, LoD ≤0.1 mg\/L) stratifies residual inflammatory risk beyond LDL-C control. N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (hs-cTnI, Roche Elecsys platform, 99th-percentile URL) screen for subclinical myocardial stress and early heart failure. Homocysteine (HPLC enzymatic, µmol\/L), fibrinogen (Clauss method, g\/L), and D-dimer (VIDAS immunoassay, µg\/mL FEU) complete the thromboinflammatory axis.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eAdvanced Lipid Panel:\u003c\/strong\u003e Beyond standard LDL-C, the protocol measures lipoprotein(a) [Lp(a), isoform-independent immunoturbidimetric assay, reported in nmol\/L per EAS Consensus Statement 2022], oxidised LDL (oxLDL, mU\/L, ELISA), apolipoprotein B (ApoB, g\/L, immunonephelometry — direct measure of atherogenic particle count), and apolipoprotein A-1 (ApoA-1, g\/L) with ApoB\/ApoA-1 ratio computed. These analytes identify atherogenic dyslipidaemia undetected by conventional LDL-C measurement.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eGenetic Cardiovascular Polygenic Risk Score (CAD-PRS):\u003c\/strong\u003e A validated multi-SNP coronary artery disease polygenic risk score (CAD-PRS, ≥6.6 million SNPs, genome-wide chip genotyping) places the individual's inherited CAD susceptibility in population-referenced percentile tiers (quintiles\/deciles). Individuals in the top 5% carry risk equivalent to a monogenic familial hypercholesterolaemia mutation. Results are interpreted in conjunction with measured biomarkers per the American Heart Association 2023 Precision Medicine Advisory.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eArterial Stiffness — Pulse Wave Velocity (PWV):\u003c\/strong\u003e Carotid-femoral pulse wave velocity (cf-PWV, m\/s, applanation tonometry) measures aortic stiffness — an independent predictor of cardiovascular events validated in the CAFE, ADVANCE, and Framingham Offspring cohorts. Results are age\/sex\/blood-pressure-referenced per ESH\/ESC 2023 hypertension guidelines (pathological threshold: cf-PWV \u0026gt;10 m\/s).\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eCarotid Intima-Media Thickness (CIMT) Ultrasound:\u003c\/strong\u003e B-mode ultrasound of the common carotid artery bilateral segments (ASE\/EACVI 2008 protocol, automated edge-detection software) measures intima-media thickness in millimetres and identifies carotid atherosclerotic plaque. CIMT \u0026gt;75th age\/sex percentile reclassifies intermediate-risk individuals to high risk per ACC\/AHA 2018 guidelines; plaque presence is independently associated with 2× increased MACE risk (CAPS, Rotterdam Study, MESA).\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eResting 12-Lead ECG:\u003c\/strong\u003e Physician-reported resting electrocardiogram screens for left ventricular hypertrophy (Sokolow-Lyon\/Cornell voltage criteria), ST-T abnormalities, conduction defects (LBBB, RBBB, fascicular blocks), QTc prolongation (Bazett\/Fridericia formula, ms), and arrhythmias including silent atrial fibrillation. ECG LVH independently adds predictive value for incident heart failure and stroke beyond conventional risk factors.\u003cbr\u003e\u003cbr\u003e\n\u003cstrong\u003eComposite Risk Outputs:\u003c\/strong\u003e Heart Health Age (HHA) — the age of a normotensive, non-smoking, lipid-optimal reference individual carrying equivalent cardiovascular risk — is calculated from the full biomarker + imaging dataset. 10-year ASCVD risk is computed via Pooled Cohort Equations (PCE, ACC\/AHA 2013, updated 2023) and SCORE2 (European SCORE2 Working Group 2021) with reclassification where indicated. Lifetime ASCVD risk (Framingham Lifetime Risk model) contextualises risk for shared decision-making. All results delivered in a structured physician report with evidence-based intervention recommendations.\n\u003c\/div\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eHeart Shield Elite — Assessment Protocol Specifications\u003c\/h2\u003e\n\u003ctable style=\"width:100%;border-collapse:collapse;font-size:14px;margin-bottom:28px;\"\u003e\n\u003cthead\u003e\n\u003ctr style=\"background:#0057a8;color:#fff;\"\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:26%;\"\u003eAssessment Domain\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:30%;\"\u003eAnalyte \/ Parameter\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:22%;\"\u003eMethod \/ Platform\u003c\/th\u003e\n\u003cth style=\"padding:10px 14px;text-align:left;width:22%;\"\u003eReference Standard\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eInflammatory Markers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ehsCRP (mg\/L), Fibrinogen (g\/L), Homocysteine (µmol\/L), IL-6 (pg\/mL)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eIFCC-standardised immunoassay; Clauss coagulation\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eISO 15189:2022; IFCC Reference Preparations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eCardiac Biomarkers\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eNT-proBNP (pg\/mL), hs-cTnI (ng\/L), D-dimer (µg\/mL FEU)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eRoche Elecsys electrochemiluminescence; VIDAS immunoassay\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eESC 2021 HF Guidelines; ESC 2020 NSTEMI Guidelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eAdvanced Lipid Panel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eLp(a) (nmol\/L), ApoB (g\/L), ApoA-1 (g\/L), oxLDL (mU\/L), ApoB\/ApoA-1 ratio\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eIsoform-independent immunoturbidimetry; ELISA (oxLDL)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eEAS Lp(a) Consensus 2022; ESC\/EAS Dyslipidaemia Guidelines 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eGenetic CAD-PRS\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eCoronary Artery Disease Polygenic Risk Score (≥6.6M SNPs)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eGenome-wide SNP chip; LDpred2 \/ PRSice-2 algorithm\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eAHA 2023 Precision Medicine Advisory; Khera et al. NatGen 2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eArterial Stiffness PWV\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eCarotid-femoral PWV (m\/s); Augmentation Index (AIx@75)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eApplanation tonometry (SphygmoCor)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eESH\/ESC 2023 Hypertension Guidelines; Laurent et al. EHJ 2006\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eCIMT Ultrasound\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eCommon carotid IMT bilateral (mm); plaque characterisation\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eB-mode ultrasound, automated edge detection (QIMT)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eASE\/EACVI 2008 Protocol; ACC\/AHA 2018 Cholesterol Guidelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eElectrocardiography\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eResting 12-lead ECG: LVH criteria, QTc (ms), rhythm, ST-T changes\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eDigital ECG acquisition; physician interpretation\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eAHA\/ACC\/HRS 2009 ECG Standardisation; Bazett\/Fridericia QTc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eComposite Risk Scores\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eHeart Health Age; 10-year ASCVD (PCE + SCORE2); Lifetime ASCVD Risk\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003ePooled Cohort Equations; SCORE2; Framingham Lifetime Risk Model\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eACC\/AHA 2013\/2023; SCORE2 Working Group EHJ 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eReport Deliverable\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eIntegrated physician report; personalised cardiac protection protocol\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eEvidence-based intervention recommendations\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eSingapore MOH Cardiovascular Prevention CPG; ACC\/AHA 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003e\u003cstrong\u003eLaboratory Accreditation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eISO 15189:2022 medical laboratory; CAP-accredited partner sites\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eExternal quality assurance: EQAS, RIQAS, Bio-Rad Liquichek\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;border-bottom:1px solid #e0e0e0;\"\u003eISO 15189:2022; Singapore HSA Laboratory Licensing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background:#f9f9f9;\"\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003e\u003cstrong\u003eTurnaround Time\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003e14–21 working days (all components)\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eBlood draw + vascular imaging appointment\u003c\/td\u003e\n\u003ctd style=\"padding:9px 14px;\"\u003eSingapore delivery; telehealth results review available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch2 style=\"color:#0057a8;font-size:20px;margin-top:32px;\"\u003eClinical Q\u0026amp;A — Heart Shield Elite\u003c\/h2\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ1: Why is ApoB superior to LDL-C as a therapeutic target, and what does Heart Shield Elite add beyond a standard lipid panel?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eStandard LDL-C (Friedewald or Martin-Hopkins calculation) estimates the cholesterol mass within LDL particles but does not directly count atherogenic particles. Each LDL, IDL, VLDL, Lp(a), and chylomicron remnant carries exactly one apolipoprotein B molecule; therefore ApoB concentration is a direct, particle-number measure of atherogenic burden. Multiple Mendelian randomisation studies and the ApoB vs LDL-C Collaborative Analysis (JAMA 2021) demonstrate that ApoB is a stronger predictor of MACE than LDL-C, particularly in patients with metabolic syndrome, hypertriglyceridaemia, or insulin resistance — conditions producing \"small dense LDL\" with normal calculated LDL-C. Lp(a) — a genetically determined LDL-like particle with prothrombotic properties — is unmeasured in standard panels yet elevates CAD and aortic stenosis risk in approximately 20% of the global population. Heart Shield Elite measures both ApoB and Lp(a) (in nmol\/L, the unit endorsed by the EAS 2022 Consensus Statement for clinical decisions), enabling reclassification of patients who appear low-risk on conventional panels but carry significant residual atherogenic burden.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ2: How does the cardiovascular polygenic risk score (CAD-PRS) interact with measured biomarkers, and how is the result actionable?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eThe CAD-PRS aggregates the cumulative effect of millions of common genetic variants — each conferring small individual risk — into a composite score benchmarked against a reference population. Unlike monogenic familial hypercholesterolaemia (FH) mutations, a high CAD-PRS does not mandate a single intervention; rather, it identifies individuals whose cardiovascular risk trajectory is steeper than their current biomarker snapshot suggests, and for whom early, intensive prevention is cost-effective. The landmark Khera et al. 2018 Nature Genetics study demonstrated that individuals in the top 8% CAD-PRS quintile carry a threefold lifetime risk equivalent to FH carriers. Crucially, the same study showed that adherence to a healthy lifestyle attenuated CAD incidence by approximately 46% even in the highest genetic risk group — establishing that high CAD-PRS is not deterministic but actionable. Heart Shield Elite integrates CAD-PRS results with hsCRP (inflammatory risk), Lp(a) (fixed atherogenic burden), and CIMT\/PWV (subclinical vascular damage) to produce a biologically coherent risk narrative: genetic predisposition × current inflammatory state × existing arterial injury = personalised risk tier and intervention intensity.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ3: What is the clinical utility of carotid intima-media thickness (CIMT) ultrasound in an asymptomatic individual?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eCIMT ultrasound provides a direct, non-invasive measure of subclinical atherosclerosis — the preclinical stage during which arterial wall thickening and plaque accumulation occur decades before symptomatic CAD, stroke, or peripheral arterial disease. In intermediate-risk individuals (10-year PCE 7.5–20%), ACC\/AHA 2018 Cholesterol Guidelines designate CIMT as a risk-enhancing factor capable of upward-reclassifying borderline risk patients to statin initiation thresholds (Class IIa recommendation). Population studies — including the Multi-Ethnic Study of Atherosclerosis (MESA), Rotterdam Study, and Carotid Atherosclerosis Progression Study (CAPS) — demonstrate that CIMT \u0026gt;75th age\/sex percentile independently doubles the risk of subsequent myocardial infarction and stroke. Carotid plaque presence (echogenic or mixed lesion ≥1.5 mm or ≥50% lumen narrowing) is associated with a 2–3× increase in MACE after controlling for Framingham risk score. The ASE\/EACVI protocol used in Heart Shield Elite employs automated edge-detection software (QIMT) to eliminate operator variability and ensure reproducible, guideline-compliant measurements bilaterally.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:20px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ4: Can elevated hsCRP, NT-proBNP, or homocysteine results be acted upon in isolation, or must they be interpreted within the full Heart Shield Elite report?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eIsolated biomarker elevation requires contextualisation; standalone interpretation risks both over- and under-treatment. hsCRP is a nonspecific acute-phase reactant elevated by infections, autoimmune conditions, obesity, and physical trauma — its cardiovascular predictive value (as established in the JUPITER trial, Ridker et al.) is valid only when LDL-C is controlled and acute illness is excluded. NT-proBNP similarly rises with atrial fibrillation, renal dysfunction, anaemia, and pulmonary hypertension beyond primary myocardial stress. Homocysteine elevation reflects nutritional deficiency (B12, folate, B6), renal insufficiency, or genetic hyperhomocysteinaemia (MTHFR C677T, CBS mutation) — and while associated with cardiovascular risk in observational data, B-vitamin supplementation has not uniformly reduced MACE in RCTs (VISP, NORVIT), necessitating careful clinical interpretation. Heart Shield Elite's integrated physician report interprets each analyte within the full clinical context — genetic predisposition, arterial stiffness, structural ECG changes, and composite risk scores — ensuring that intervention recommendations are calibrated, evidence-based, and aligned with ACC\/AHA 2023 and Singapore MOH Clinical Practice Guidelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cdiv style=\"margin-bottom:28px;padding:16px 20px;background:#fafcff;border:1px solid #d0e4f7;border-radius:6px;\"\u003e\n\u003cp style=\"font-weight:700;color:#0057a8;margin-bottom:8px;\"\u003eQ5: What specific interventions does the personalised cardiac protection protocol recommend for different risk tiers?\u003c\/p\u003e\n\u003cp style=\"margin:0;line-height:1.7;\"\u003eThe personalised cardiac protection protocol generated by Heart Shield Elite stratifies individuals into three actionable risk tiers based on composite biomarker, imaging, genetic, and ECG findings. \u003cstrong\u003eTier A (low-intermediate composite risk, Heart Health Age ≤5 years above chronological age, 10-year ASCVD \u0026lt;7.5%):\u003c\/strong\u003e Lifestyle optimisation protocol — dietary intervention targeting Mediterranean-pattern adherence (PREDIMED-Plus evidence base), structured aerobic exercise (≥150 min\/week moderate-intensity, ACC\/AHA Class I), sleep hygiene optimisation, and 12-month reassessment schedule. \u003cstrong\u003eTier B (intermediate-high risk, Heart Health Age 5–15 years above chronological, 10-year ASCVD 7.5–20%, or presence of CIMT plaque\/elevated Lp(a)\/high CAD-PRS quintile):\u003c\/strong\u003e Statin initiation discussion (rosuvastatin\/atorvastatin, ACC\/AHA Class IIa–I), structured cardiologist or preventive medicine physician referral, cardiac rehabilitation-grade exercise programme, and reassessment at 6 months. \u003cstrong\u003eTier C (high-very high risk, 10-year ASCVD \u0026gt;20%, Heart Health Age \u0026gt;15 years above chronological, abnormal ECG\/NT-proBNP\/hs-cTnI, or cf-PWV \u0026gt;12 m\/s):\u003c\/strong\u003e Urgent specialist cardiology referral, intensive LDL-C reduction targeting ApoB \u0026lt;0.7 g\/L (ESC\/EAS Class I, very-high-risk), consideration of ezetimibe or PCSK9 inhibitor add-on, antihypertensive optimisation, and reassessment at 3 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\/\",\n  \"@type\": \"Product\",\n  \"name\": \"Heart Shield Elite — Advanced 360° Cardiovascular Risk Assessment\",\n  \"description\": \"EMIS+ Heart Shield Elite: comprehensive cardiovascular risk assessment integrating hsCRP, NT-proBNP, hs-cTnI, homocysteine, fibrinogen, D-dimer, Lp(a), ApoB, ApoA-1, oxidised LDL, CAD polygenic risk score, carotid-femoral PWV, CIMT ultrasound, resting 12-lead ECG, Heart Health Age, 10-year ASCVD (PCE\/SCORE2), lifetime ASCVD risk, and personalised cardiac protection protocol. ISO 15189:2022 accredited. Singapore.\",\n  \"sku\": \"EMIS-HSE-899\",\n  \"brand\": {\n    \"@type\": \"Brand\",\n    \"name\": \"EMIS+\"\n  },\n  \"offers\": {\n    \"@type\": \"Offer\",\n    \"priceCurrency\": \"SGD\",\n    \"price\": \"899.00\",\n    \"availability\": \"https:\/\/schema.org\/InStock\",\n    \"url\": \"https:\/\/www.emis.asia\/products\/heart-shield-elite\"\n  },\n  \"additionalProperty\": [\n    {\"@type\": \"PropertyValue\", \"name\": \"Inflammatory Markers\", \"value\": \"hsCRP, fibrinogen, homocysteine, IL-6 — IFCC-standardised\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Cardiac Biomarkers\", \"value\": \"NT-proBNP, hs-cTnI, D-dimer — Roche Elecsys platform\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Advanced Lipid Panel\", \"value\": \"Lp(a) nmol\/L, ApoB g\/L, ApoA-1, oxidised LDL, ApoB\/ApoA-1 ratio\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Genetic CAD-PRS\", \"value\": \"Coronary Artery Disease Polygenic Risk Score ≥6.6M SNPs\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Arterial Stiffness\", \"value\": \"Carotid-femoral PWV m\/s; Augmentation Index AIx@75\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"CIMT Ultrasound\", \"value\": \"Bilateral common carotid IMT mm; plaque characterisation; ASE\/EACVI protocol\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Electrocardiography\", \"value\": \"Resting 12-lead ECG; LVH criteria; QTc ms; rhythm analysis\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Risk Scores\", \"value\": \"10-year ASCVD PCE + SCORE2; Lifetime ASCVD; Heart Health Age\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Laboratory Accreditation\", \"value\": \"ISO 15189:2022; CAP-accredited partner laboratories\"},\n    {\"@type\": \"PropertyValue\", \"name\": \"Regulatory Compliance\", \"value\": \"Singapore HSA; ACC\/AHA 2023; ESC\/EAS 2021; Singapore MOH CPG\"}\n  ]\n}\n\u003c\/script\u003e\n\n\u003cdiv style=\"margin-top:28px;padding:14px 18px;background:#f5f5f5;border-radius:6px;font-size:13px;color:#444;line-height:1.65;\"\u003e\n\u003cstrong\u003eRegulatory and Methodological Framework:\u003c\/strong\u003e Heart Shield Elite is conducted within an ISO 15189:2022-accredited medical laboratory network with CAP (College of American Pathologists) external quality assurance programmes including EQAS, RIQAS, and Bio-Rad Liquichek. All biochemical assays comply with IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) reference measurement procedures and WHO\/IFCC International Reference Preparations where applicable. Genetic CAD polygenic risk scoring methodology follows the Khera et al. 2018 Nature Genetics landmark study (PRSice-2 \/ LDpred2 algorithms) and the American Heart Association 2023 Precision Medicine in Cardiovascular Disease Advisory. Advanced lipid reporting (Lp(a) in nmol\/L) complies with the 2022 European Atherosclerosis Society (EAS) Lipoprotein(a) Consensus Statement. Arterial stiffness measurement follows ESH\/ESC 2023 hypertension guidelines pathological thresholds. CIMT protocol adheres to ASE\/EACVI 2008 consensus standards. 10-year cardiovascular risk is computed via the 2013\/2023 ACC\/AHA Pooled Cohort Equations (PCE) and the European SCORE2 algorithm (SCORE2 Working Group, European Heart Journal 2021). Lifetime ASCVD risk uses the Framingham Heart Study Lifetime Risk model. All clinical interpretation and cardiac protection protocol recommendations are aligned with ACC\/AHA 2023 Cardiovascular Prevention Guidelines, ESC\/EAS 2021 Dyslipidaemia Management Guidelines, and Singapore Ministry of Health Clinical Practice Guidelines on Cardiovascular Prevention. This assessment is conducted under the supervision of MOH-registered physicians in Singapore. Results are not intended to replace clinical consultation; participants with abnormal findings are advised to seek specialist cardiology review. Heart Shield Elite is indicated for adults aged 30–75 years with no prior MACE who are seeking proactive cardiovascular risk quantification and evidence-based prevention.\n\u003c\/div\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What are the benefits of Heart Shield Elite?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Heart Shield Elite by EMIS + supports general health and wellbeing as part of a balanced diet and healthy lifestyle. As with all supplements, individual results may vary. Consult your doctor or pharmacist before starting any new supplement, especially if you have existing medical conditions or are taking medications.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Who should take Heart Shield Elite?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Heart Shield Elite may be suitable for adults looking to support their health and address specific nutritional needs. It may be particularly beneficial for individuals with dietary gaps, those recovering from illness or surgery, or those with increased nutritional demands. Always consult a healthcare professional — your GP, pharmacist, or dietitian — before starting supplementation, especially during pregnancy, breastfeeding, or if you have a chronic condition.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is the recommended dosage for Heart Shield Elite?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Follow the dosage instructions on the Heart Shield Elite product label or as directed by your healthcare provider. Do not exceed the recommended daily intake. If you experience any adverse reactions, discontinue use and consult a doctor. EMIS+ recommends consulting a Singapore-registered pharmacist or GP for personalised supplement advice.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Heart Shield Elite in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Heart Shield Elite is available from EMIS+ at emis.asia with fast island-wide Singapore delivery. We stock a wide range of quality health supplements from trusted brands. Visit emis.asia or contact our team for product advice and bulk ordering.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"EMIS +","offers":[{"title":"Default Title","offer_id":43525991399502,"sku":null,"price":899.0,"currency_code":"SGD","in_stock":true}],"url":"https:\/\/www.emis.asia\/zh\/products\/heart-shield-elite","provider":"EMIS +","version":"1.0","type":"link"}